ABEONA THERAPEUT. DL-01 - Asset Resilience Ratio

Latest as of December 2025: 51.45%

ABEONA THERAPEUT. DL-01 (PCJ) has an Asset Resilience Ratio of 51.45% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

€112.97 Million

≈ $132.07 Million USD Cash + Short-term Investments

Total Assets

€219.57 Million

≈ $256.70 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2021–2025)

This chart shows how ABEONA THERAPEUT. DL-01's Asset Resilience Ratio has changed over time. See financial flexibility index of ABEONA THERAPEUT. DL-01 to measure the company's free cash flow as a share of total liabilities.

Liquid Assets Composition Over Time

This chart breaks down ABEONA THERAPEUT. DL-01's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see PCJ market cap overview.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€112.97 Million	51.45%
Total Liquid Assets	€112.97 Million	51.45%

Asset Resilience Insights

Very High Liquidity: ABEONA THERAPEUT. DL-01 maintains exceptional liquid asset reserves at 51.45% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

ABEONA THERAPEUT. DL-01 Industry Peers by Asset Resilience Ratio

Compare ABEONA THERAPEUT. DL-01's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Royalty Pharma Plc NASDAQ:RPRX	Biotechnology	0.11%
Tubize-Fin BR:TUB	Biotechnology	0.05%
Cidara Therapeutics Inc NASDAQ:CDTX	Biotechnology	24.37%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
Genscript Biotech Corporation F:G51	Biotechnology	13.79%
Pharming Group NV NASDAQ:PHAR	Biotechnology	24.07%
Guangzhou Boji Medical and Biotechnological Co Ltd SHE:300404	Biotechnology	13.78%
Shanghai Shen Lian Biomedical Corp SHG:688098	Biotechnology	0.69%

Annual Asset Resilience Ratio for ABEONA THERAPEUT. DL-01 (2021–2025)

The table below shows the annual Asset Resilience Ratio data for ABEONA THERAPEUT. DL-01.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	51.45%	€112.97 Million ≈ $132.07 Million	€219.57 Million ≈ $256.70 Million	-16.82pp
2024-12-31	68.27%	€74.36 Million ≈ $86.94 Million	€108.93 Million ≈ $127.35 Million	+9.28pp
2023-12-31	58.99%	€37.75 Million ≈ $44.14 Million	€64.00 Million ≈ $74.83 Million	-0.08pp
2022-12-31	59.07%	€37.93 Million ≈ $44.35 Million	€64.21 Million ≈ $75.07 Million	+43.89pp
2021-12-31	15.19%	€12.09 Million ≈ $14.13 Million	€79.59 Million ≈ $93.04 Million	--

pp = percentage points

About ABEONA THERAPEUT. DL-01

F:PCJ Germany Biotechnology

Market Cap

$363.76 Million

€311.15 Million EUR

Market Cap Rank

#14935 Global

#1487 in Germany

Share Price

€5.47

Change (1 day)

+0.00%

52-Week Range

€3.56 - €6.28

All Time High

€17.73